Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a neutral rating to a buy rating in a research report sent to investors on Friday, MarketBeat Ratings reports. They currently have $370.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $198.00.

A number of other research analysts have also recently issued reports on the stock. TD Cowen increased their target price on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a buy rating in a report on Tuesday, June 25th. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a buy rating in a report on Tuesday, June 25th. Royal Bank of Canada upped their target price on Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the company an outperform rating in a report on Friday, August 2nd. Citigroup lifted their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a buy rating in a research note on Friday, August 2nd. Finally, UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a buy rating in a research report on Friday, June 28th. Seven research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $277.14.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $268.24 on Friday. The business’s fifty day moving average price is $232.23 and its 200 day moving average price is $180.32. The firm has a market capitalization of $33.93 billion, a PE ratio of -100.09 and a beta of 0.37. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $274.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.21) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the sale, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,848 shares of company stock valued at $24,683,444. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth about $26,000. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $30,000. Robeco Institutional Asset Management B.V. lifted its position in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $52,000. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.